A Simulation Shows That Early Treatment Of Chronic Hepatitis B Infection Can Cut Deaths And Be Cost-Effective
A Simulation Shows That Early Treatment Of Chronic Hepatitis B Infection Can Cut Deaths And Be Cost-Effective
复制标题
DOI：
10.1377/hlthaff.2008.0905
复制
发表时间：
2011-02-01
期刊：
影响因子：
9.7
通讯作者：
Pollack, Henry J.
中科院分区：
文献类型：
--
作者：
Post, Sarah E.;Sodhi, Neetu Khurana;Pollack, Henry J.
慢性B型肝炎影响美国80万至200万人，每年导致4,000人死亡。然而，治疗的成本和效益尚未得到充分评估。使用一个模拟疾病进展的模型，我们比较了在疾病早期开始的B型肝炎治疗方案与在晚期开始的治疗方案。我们的分析得出结论，早期B型肝炎护理可以改善健康状况，减少过早死亡，并预防昂贵的并发症，使其具有高度的长期成本效益。我们的研究结果证明了在高危人群中筛查B型肝炎并将筛查与治疗联系起来的重要性。它们还说明了预测模型如何用于评估改善医疗服务的战略。
Chronic hepatitis B affects between 800,000 and two million people in the United States and causes 4,000 deaths each year. Yet the costs and benefits of treatment have not been fully evaluated. Using a model that simulates disease progression, we compare treatment programs for hepatitis B that start at an early stage of the disease to treatment that begins at a late stage. Our analysis concludes that early hepatitis B care can improve health, reduce premature deaths, and prevent expensive complications, making it highly cost-effective in the long term. Our results demonstrate the importance of screening for hepatitis B among at-risk groups and then linking screening to treatment. They also illustrate how predictive models can be used to evaluate strategies for improving access to care.